Advertisement

Management of treatment nonresponse

Chapter
  • 1.7k Downloads

Abstract

Inadequate treatment response is unfortunately a common problem. Approximately 50–70% of patients gain significant benefit from treatment but, of these, not all will have symptomatic remission [1]. An approximate rule of thirds applies, with a third achieving remission, a third being significantly better but not symptom free with partial remission, and a third remaining depressed. These proportions depend on the duration of follow-up and the nature of the population being studied. Consideration of next-step treatments is therefore extremely important and a pessimist might say that the next step should be planned at the time of the first step. It is certainly important to plan treatment in the knowledge that further steps might be needed.

Keywords

Partial Remission Symptomatic Remission Augmentation Strategy Discontinuation Symptom Lithium Augmentation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Curr Psychiatry Rep 2005; 7: 441–446.PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson I, Ferrier I, Baldwin R, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22:343–396.PubMedCrossRefGoogle Scholar
  3. 3.
    Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917.PubMedCrossRefGoogle Scholar
  4. 4.
    Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917.PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson IM. Drug treatment of depression: reflections on the evidence. Adv Psychiatr Treat 2003; 9:11–20.CrossRefGoogle Scholar
  6. 6.
    Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255:387–400.PubMedCrossRefGoogle Scholar
  7. 7.
    Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 2008; 59:116–122.CrossRefGoogle Scholar
  8. 8.
    Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63:331–336.PubMedCrossRefGoogle Scholar
  9. 9.
    Ruhe HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006; 67:1836–1855.PubMedCrossRefGoogle Scholar
  10. 10.
    Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines, 9th edition. London: Informa Healthcare, 2007.Google Scholar
  11. 11.
    Rojo JE, Ros S, Aguera L, et al. Combined antidepressants: clinical experience. Acta Psychiatr Scand 2005; 112(Suppl 428):25–31.CrossRefGoogle Scholar
  12. 12.
    Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935–940.PubMedCrossRefGoogle Scholar
  13. 13.
    Papakostas GI, Shelton RC, Smith J, et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007; 68:826–831.PubMedCrossRefGoogle Scholar
  14. 14.
    Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007; 164:739–752.PubMedCrossRefGoogle Scholar
  15. 15.
    Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999; 56:829–835.PubMedCrossRefGoogle Scholar
  16. 16.
    Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61:714–719.PubMedCrossRefGoogle Scholar
  17. 17.
    Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54:1009–1015.PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  1. 1.Neuroscience and Psychiatry Unit Mental Health and Neurodegeneration Research Group, School of MedicineUniversity of ManchesterManchesterUK

Personalised recommendations